Literature DB >> 16924387

The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.

Ya-Huei Liou1, Chien-Ting Lin1, Ying-Jye Wu1, Lawrence Shih-Hsin Wu2.   

Abstract

Genetic polymorphisms of drug metabolizing enzymes, such as cytochromes P450 (CYPs), play major roles in the variations of drug responsiveness in human. The aim of this study is to identify the high prevalence (minor allele frequencies >1%) of the abnormal metabolite alleles of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Taiwanese population. The genotyping of the functional single nucleotide polymorphisms (SNPs) of CYPs were conducted by direct exon sequencing in 180 Taiwanese volunteers. Twenty-one unique SNPs including three newly identified SNPs were detected in the Taiwanese population. Six of the 21 SNPs in five genes showed frequencies more than 1%. The results indicated that it could be very useful and important in developing an inexpensive, convenient, and precise genotyping method for the high prevalence of CYPs metabolizing abnormal alleles in the Taiwanese population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16924387     DOI: 10.1007/s10038-006-0034-0

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  32 in total

1.  Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19.

Authors:  Takako Shimizu; Hirohide Ochiai; Fredrik Asell; Hiroshi Shimizu; Ryuta Saitoh; Yoshimasa Hama; Jun Katada; Munehiro Hashimoto; Hitoshi Matsui; Katsuhiko Taki; Tsuguchika Kaminuma; Michiko Yamamoto; Yoshitaka Aida; Akira Ohashi; Naoki Ozawa
Journal:  Drug Metab Pharmacokinet       Date:  2003       Impact factor: 3.614

2.  Genetic polymorphism of human cytochrome p450 involved in drug metabolism.

Authors:  Kiyoshi Nagata; Yasushi Yamazoe
Journal:  Drug Metab Pharmacokinet       Date:  2002       Impact factor: 3.614

3.  Factors determining the maintenance dose of warfarin in Chinese patients.

Authors:  H C Yu; T Y Chan; J A Critchley; K S Woo
Journal:  QJM       Date:  1996-02

4.  Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.

Authors:  D Dai; J Tang; R Rose; E Hodgson; R J Bienstock; H W Mohrenweiser; J A Goldstein
Journal:  J Pharmacol Exp Ther       Date:  2001-12       Impact factor: 4.030

5.  A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial.

Authors:  A M Ross; R Gao; K S Coyne; J Chen; K Yao; Y Yang; X Qin; S Qiao; M Yao
Journal:  Am Heart J       Date:  2001-08       Impact factor: 4.749

6.  Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

Authors:  M G Scordo; E Aklillu; U Yasar; M L Dahl; E Spina; M Ingelman-Sundberg
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

Review 7.  Pharmacogenomics: the inherited basis for interindividual differences in drug response.

Authors:  W E Evans; J A Johnson
Journal:  Annu Rev Genomics Hum Genet       Date:  2001       Impact factor: 8.929

8.  Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.

Authors:  K Herrlin; A Y Massele; M Jande; C Alm; G Tybring; Y A Abdi; A Wennerholm; I Johansson; M L Dahl; L Bertilsson; L L Gustafsson
Journal:  Clin Pharmacol Ther       Date:  1998-10       Impact factor: 6.875

9.  Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.

Authors:  Joseph F Solus; Brenda J Arietta; James R Harris; David P Sexton; John Q Steward; Chara McMunn; Patrick Ihrie; Janelle M Mehall; Todd L Edwards; Elliott P Dawson
Journal:  Pharmacogenomics       Date:  2004-10       Impact factor: 2.533

10.  Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.

Authors:  J A Goldstein; T Ishizaki; K Chiba; S M de Morais; D Bell; P M Krahn; D A Evans
Journal:  Pharmacogenetics       Date:  1997-02
View more
  7 in total

1.  Developing and Evaluating the HRM Technique for Identifying Cytochrome P450 2D6 Polymorphisms.

Authors:  Hsiu-Chin Lu; Ya-Sian Chang; Chun-Chi Chang; Ching-Hsiung Lin; Jan-Gowth Chang
Journal:  J Clin Lab Anal       Date:  2014-05-05       Impact factor: 2.352

Review 2.  Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes.

Authors:  Tingyu Wang; Yitian Zhou; Guosheng Cao
Journal:  Eur J Clin Pharmacol       Date:  2021-01-29       Impact factor: 2.953

3.  Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone.

Authors:  Yaowaluck Hongkaew; Andrea Gaedigk; Bob Wilffert; Nattawat Ngamsamut; Wiranpat Kittitharaphan; Penkhae Limsila; Chonlaphat Sukasem
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

4.  Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS).

Authors:  E Bothos; E Ntoumou; K Kelaidoni; D Roukas; N Drakoulis; M Papasavva; F A Karakostis; P Moulos; K Karakostis
Journal:  J Transl Med       Date:  2021-04-15       Impact factor: 5.531

5.  Clopidogrel Use and CYP2C19 Genotypes in Patients Undergoing Vascular Intervention Procedure: A Hospital-Based Study.

Authors:  Yi-Ming Chen; Ming-Fen Wu; Yi-Ju Liao; Tzu-Hung Hsiao; Ching-Heng Lin; Chun-Sheng Hsu; Yen-Lin Chang; Yu-Wei Chen; Chiann-Yi Hsu
Journal:  Pharmgenomics Pers Med       Date:  2022-02-02

6.  CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel.

Authors:  Yu-Wei Chen; Yi-Ju Liao; Wei-Chun Chang; Tzu-Hung Hsiao; Ching-Heng Lin; Chiann-Yi Hsu; Tsun-Jui Liu; Wen-Lieng Lee; Yi-Ming Chen
Journal:  Front Cardiovasc Med       Date:  2022-08-22

7.  Comparison Between Aspirin and Clopidogrel in Secondary Stroke Prevention Based on Real-World Data.

Authors:  Nai-Fang Chi; Chi-Pang Wen; Chung-Hsiang Liu; Jie-Yuan Li; Jiann-Shing Jeng; Chih-Hung Chen; Li-Ming Lien; Ching-Huang Lin; Yu Sun; Wei-Lun Chang; Chaur-Jong Hu; Chung Y Hsu
Journal:  J Am Heart Assoc       Date:  2018-10-02       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.